Notificação de acontecimentos adversos ou reclamações de qualidade
AZ Medical Global

Áreas Terapêuticas
Medicamentos
Recursos
Conectar

Login

Search Medical Information

Para pesquisar informação científica, deverá especificar pelo menos dois termos de pesquisa

Search Medical Information

ESMO Breast Cancer 2024

May 15 - 17, 2024

Trastuzumab deruxtecan
Camizestrant
Capivasertib
Datopotamab deruxecan

pdf

A health-related quality-of-life (HRQoL) analysis from DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) vs capecitabine (CAP) in patients (Pts) with hormone receptor–positive (HR+), HER2-low metastatic breast cancer (mBC)

pdf

Safety, tolerability, and antitumor activity of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+ metastatic breast cancer (mBC) and active brain metastases (BM) in DESTINY-Breast07 (DB-07)

pdf

Exploratory pooled safety analysis of trastuzumab deruxtecan (T-DXd) in patients with HER2+ or HER2-low unresectable and/or metastatic breast cancer (mBC) in DESTINY-Breast trials

pdf

PROVIDENCE: A prospective, non-interventional study examining real-world clinical and patient-reported outcome (PRO) data in patients (pts) with HER2-positive or HER2-low unresectable or metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd)

pdf

Trastuzumab deruxtecan (T-DXd) vs Treatment of Physicians' choice (TPC) in patients with HER2+ metastatic breast cancer (mBC) previously treated with trastuzumab emtansine (T-DM1): Updated Overall Survival (OS) Results of the randomized, phase 3 DESTINY-Breast02 (DB02)

pdf

Trastuzumab deruxtecan (T-DXd) for Advanced Breast Cancer (ABC) patients (pts), regardless of HER2 status: A phase II study with Biomarkers Analysis (DAISY) Update analysis with longer follow-up

pdf

Dynamics of ESR1m ctDNA in patients with ER+ HER2- metastatic breast cancer receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial.

pdf

Capivasertib and fulvestrant for patients with AI-resistant HR+/HER2– ABC: PFS2 and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial

ppt

TROPION-Breast04: Phase (Ph) 3 study of neoadjuvant (neoadj) datopotamab deruxtecan (Dato-DXd) + durvalumab (durva) followed by adjuvant (adj) durva vs standard of care (SoC) in treatment-naïve, triple-negative (TN) and HR-low/HER2– breast cancer (BC)

ppt

TROPION-Breast05: Phase (Ph) 3 study of datopotamab deruxtecan (Dato-DXd) ± durvalumab (durva) vs chemotherapy (CT) + pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)

ppt

Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable/metastatic HR+/HER2- breast cancer (BC): Additional safety analysis from TROPION-Breast01

Não encontra o que procura?

Contacte-nos

Encontre um Medical Healthcare Partner

Submeter uma questão

A informação incluída neste website é dirigida exclusivamente a profissionais de saúde.

©2024 AstraZeneca. Todos os direitos reservados. PT-19636

Aprovado a 12/2024.

Sobre o AZMedical

AstraZeneca Portugal

Inquérito de Satisfação

Política de Privacidade

Aviso Legal e Termos de Utilização

Notificação de acontecimentos adversos ou reclamações de qualidade

Política de Privacidade

Aviso Legal e Termos de Utilização